Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FibroBiologics, Inc.FBLG · Entity 7875 | Chief Scientific Officer | September 15, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FibroBiologics, Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 301,571 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 298,508 · Balance 301,571 F1: On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering"). F2: Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2031-09-15 | Direct | 298,508 |
Reported balance
After 2026-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-15 · Grant · Acquired 298,508 · Balance 298,508 F1: On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering"). F2: Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675. F3: The warrants are exercisable at any time until they expire. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering").
F2: Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675.
F3: The warrants are exercisable at any time until they expire.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 15, 2026 23:26 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantWarrant (Right to Buy) · Derivative | 298,508 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001493152-26-042794 · ownership.xml · derivative · entry 2 Khoja Hamid · CIK 0002010662 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,508 Underlying: Common Stock · 298,508 shares Expires 2031-09-15 F1 · kind: On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering"). F2 · price: Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675. F3 · derivative.exercise_date: The warrants are exercisable at any time until they expire. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:26 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantCommon Stock | 298,508 | $1.68 | $500,000.90 |
DisclosureSEC source: 0001493152-26-042794 · ownership.xml · nonDerivative · entry 1 Khoja Hamid · CIK 0002010662 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,571 F1 · kind: On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering"). F2 · price: Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:00 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 61,607 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-26-021174 · ownership.xml · derivative · entry 1 Khoja Hamid · CIK 0002010662 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,607 Underlying: Common Stock · 61,607 shares Expires 2036-05-04 F1 · derivative.exercise_date: On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 13:00 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | PurchaseCommon Stock | 30,000 | $0.38 | $11,400.00 |
DisclosureSEC source: 0001493152-26-008933 · ownership.xml · nonDerivative · entry 1 Khoja Hamid · CIK 0002010662 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,250 Read SEC document |
| May 27, 2025 Filed May 27, 2025 21:56 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | PurchaseCommon Stock | 20,000 | $0.84 | $16,800.00 |
DisclosureSEC source: 0001641172-25-012539 · ownership.xml · nonDerivative · entry 1 Khoja Hamid · CIK 0002010662 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:10 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 189,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001641172-25-001187 · ownership.xml · derivative · entry 1 Khoja Hamid · CIK 0002010662 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,000 Underlying: Common Stock · 189,000 shares Expires 2035-03-25 F1 · derivative.exercise_date: On March 26, 2025, the reporting person was granted an option to purchase 189,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:20 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 176,200 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001493152-24-052490 · ownership.xml · derivative · entry 1 Khoja Hamid · CIK 0002010662 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,200 Underlying: Common Stock · 176,200 shares Expires 2034-12-26 F1 · derivative.exercise_date: On December 27, 2024, the reporting person was granted an option to purchase 176,200 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 01:58 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | PurchaseCommon Stock | 10,000 | $1.90 | $19,000.00 |
DisclosureSEC source: 0001493152-24-031438 · ownership.xml · nonDerivative · entry 1 Khoja Hamid · CIK 0002010662 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.